Novavax tempers its revenue expectations as it unveils PhIII data for bivalent booster
As Novavax reports third quarter results, the vaccine maker is tempering its expectations once again on Covid-19 sales.
The company reported that it netted $725 million in Q3 and administered around 94 million doses so far, but it has lowered its financial guidance for the year further to an even $2 billion from an expected $2.3 billion just last quarter. The company also lowered its guidance from an estimated $5 billion during its Q2 results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.